Targeted Covalent Inhibition of Small CTD Phosphatase 1 to Promote the Degradation of the REST Transcription Factor...

Area of Science:

• Neuroscience
• Molecular Biology
• Oncology

Background:

• The repressor element-1 silencing transcription factor (REST) plays a critical role in neuronal gene expression.
• Dysregulation of REST is linked to neurological diseases and brain tumors, particularly glioblastoma.
• High REST protein levels can drive tumor growth in certain glioblastoma cells, making it a potential therapeutic target.

Purpose of the Study:

• To design and synthesize novel small-molecule inhibitors targeting small CTD phosphatase 1 (SCP1).
• To investigate the potential of SCP1 inhibition as a therapeutic strategy for glioblastoma by reducing REST activity.

Main Methods:

• Rational design of α,β-unsaturated sulfones as covalent inhibitors of SCP1.
• Biochemical assays to confirm covalent modification of SCP1 at Cys181.
• Cellular studies to assess inhibitor efficacy, including time- and dose-dependent inactivation of SCP1 and reduction of REST protein levels.

Main Results:

• Developed potent and selective covalent inhibitors targeting SCP1.
• Demonstrated that these inhibitors inactivate SCP1 with an EC50 of approximately 1.5 μM.
• Showed that SCP1 inhibition leads to reduced REST protein levels and activation of REST-suppressed genes in cellular models.

Conclusions:

• The designed α,β-unsaturated sulfones effectively inhibit SCP1, leading to REST degradation.
• These SCP1 inhibitors represent a promising novel therapeutic lead for glioblastoma treatment.
• Targeting SCP1 offers a new strategy to combat glioblastoma driven by REST transcription activity.